Please assess the completion status of the following clinical trial:

Trial Title: Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Recent acute coronary syndrome with ongoing ticagrelor treatment~* Stabilized clinical condition with no plans of additional revascularization~* Dyspnea with onset after start of ticagrelor treatment~* Willingness to abstain from caffeine intake (e.g. coffee, tea, cola-type beverages; other foods, nutritional supplements or medications containing caffeine) for the duration of the study~* Provision of signed informed consent form~Exclusion Criteria:~* Chronic obstructive pulmonary disease, asthma or other known pulmonary disease requiring daily medical therapy~* Obstructive sleep apnea syndrome requiring therapy~* Ongoing signs and symptoms of heart failure\*, or evidence of moderately to severely reduced left ventricular (LV) function~* Renal failure, glomerular filtration rate (GFR) \<30 or on dialysis~* Pregnancy or lactation~* Known allergy to ticagrelor, or caffeine, or known intolerance of caffeine~* Ongoing treatment with any of the following: quinolone antibiotics, fluvoxamine, phenylpropanolamine, carbamazepine, clozapine, lithium, non-steroidal anti-inflammatory drugs (NSAIDs); or any drug containing theophylline or caffeine.~* Any condition that seriously increases the risk of non-compliance or loss of follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: EXPERIMENTAL): Caffeine capsules. 200 mg twice daily orally for 7-10 days.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules twice daily orally for 7-10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).